RxDoctor Payments Data

Ricardo Varas, MD

Internal Medicine · Kissimmee, FLNPI 1134148299

Payments from drug & device makers

$3,106in general payments, 2019–2025

Across 168 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$490
  • AstraZeneca$489
  • Bayer$470
  • Lilly USA, LLC$351
  • Amarin Pharma, Inc.$279
  • Johnson & Johnson$192
  • plus $836 from 14 others

What the payments were for

  • Food & beverage$3,100100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,106 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$7,230
Medicare patients
27
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$222,468
JardianceEmpagliflozin83$119,328
EliquisApixaban82$96,428
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$60,448
RybelsusSemaglutide52$57,568
FarxigaDapagliflozin Propanediol50$52,521
TrulicityDulaglutide27$43,114
MyrbetriqMirabegron35$42,229
XareltoRivaroxaban22$25,836
LinzessLinaclotide17$23,941
MounjaroTirzepatide23$23,568
VascepaIcosapent Ethyl29$23,015
Tresiba Flextouch U-100Insulin Degludec31$15,764
TresibaInsulin Degludec13$12,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$9,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba, Novolog$490$296,380298 claims
Boehringer IngelheimJardiance$33$119,32883 claims
PfizerEliquis$136$96,42882 claims
Lilly USA, LLCTrulicity, Mounjaro$351$66,68250 claims
AstraZenecaFarxiga, Symbicort$489$60,46467 claims
GSKTrelegy Ellipta$118$60,44842 claims
Astellas Pharma US IncMyrbetriq$62$42,22935 claims
Johnson & JohnsonXarelto$192$25,83622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →